Ann: Meeting Requested with FDA on Revascor Accelerated Approval, page-125

  1. 967 Posts.
    lightbulb Created with Sketch. 348
    If meeting was requested in Jan-March quarter, can we assume that meeting is already happened or happening prior to 30th June?

    This is my chatbot is telling:

    If the Type B meeting has occurred or occurs soon, Mesoblast may announce whether the FDA has provided further clarity or agreement on the accelerated approval pathway for Revascor in patients with end-stage HFrEF. This could include details on the timeline for filing a Biologics License Application (BLA) or additional steps needed to advance toward accelerated approval.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.80
Change
-0.055(2.97%)
Mkt cap ! $2.293B
Open High Low Value Volume
$1.84 $1.86 $1.77 $7.241M 4.018M

Buyers (Bids)

No. Vol. Price($)
3 25472 $1.80
 

Sellers (Offers)

Price($) Vol. No.
$1.81 1500 1
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.